Cited by 331Attention Deficit Hyperactivity DisorderPharmacovigilance and Adverse Drug ReactionsPharmacology and Obesity Treatment

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

ADHD Drugs and Cardiovascular Risk

Nissen, Steven E.·2006·New England Journal of Medicine

DOI 10.1056/nejmp068049

Open this paper in CoChat — free account

Abstract

On February 9, the Drug Safety and Risk Management Advisory Committee of the FDA voted to recommend a “black-box” warning describing the cardiovascular risks of stimulant drugs used to treat ADHD. Dr. Steven Nissen explains why the advisory committee took decisive action.

Integrity signals

Registry

Crossref · 10.1056/nejmp068049

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T. G., Feldmann, E. G., Morgenstern, L. B., Wilterdink, J. L., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432501 · Cited by 746
Contraindicated Use of Cisapride
Smalley, W. E., Shatin, D., Wysowski, D. K., Gurwitz, J. H., Andrade, S. E., Goodman, M. J., Chan, K. A., Platt, R. G., Schech, S. D., & Ray, W. A. (2000) · JAMA · doi:10.1001/jama.284.23.3036 · Cited by 253
Blood Pressure Changes Associated With Medication Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
Wilens, T. E., Hammerness, P. G., Biederman, J., Kwon, A., Spencer, T. J., Clark, S., Scott, M., Podolski, A., Ditterline, J., Morris, M. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0215 · Cited by 149
Postmarketing Surveillance of Suicidal Adverse Events with Pediatric Use of Antidepressants
Mosholder, A. D., & Pamer, C. A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.33 · Cited by 25
Report From the Cardiovascular and Renal Drugs Advisory Committee
Nissen, S. E. (2005) · Circulation · doi:10.1161/circulationaha.105.573105 · Cited by 20
Self-citation
The Relative Safety of Ephedra Compared with Other Herbal Products
Kingston, R. L., & Borron, S. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00017 · Cited by 6

Flagged first, then by citations

Show all 6 references

Sorted by citations

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
The Medicalization of Society
Conrad, P. (2007) · Johns Hopkins University Press eBooks · doi:10.56021/9780801885846 · Cited by 1,448
A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
Effectiveness of manual therapies: the UK evidence report
Bronfort, G., Haas, M., Evans, R., Leininger, B., & Triano, J. (2010) · Chiropractic & Osteopathy · doi:10.1186/1746-1340-18-3 · Cited by 434
ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110212 · Cited by 411
European guidelines on managing adverse effects of medication for ADHD
(for the European Guidelines Group), Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0140-6 · Cited by 374
The importance of relative standards in ADHD diagnoses: Evidence based on exact birth dates
Elder, T. E. (2010) · Journal of Health Economics · doi:10.1016/j.jhealeco.2010.06.003 · Cited by 336
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296
Measuring inappropriate medical diagnosis and treatment in survey data: The case of ADHD among school-age children
Evans, W. N., Morrill, M. S., & Parente, S. T. (2010) · Journal of Health Economics · doi:10.1016/j.jhealeco.2010.07.005 · Cited by 292
Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269
Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder
Stiefel, G., & Besag, F. (2010) · Drug Safety · doi:10.2165/11536380-000000000-00000 · Cited by 256
Neuropsychopharmacology
Rendleman, R. L., & Walkup, J. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 197
A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder
Medori, R., Ramos-Quiroga, J. A., Casas, M., Kooij, J. J. S., Niemelä, A., Trott, G.-E., Lee, E., & Buitelaar, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.008 · Cited by 186
Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder: Epidemiology, Prevention and Management
Graham, J., & Coghill, D. (2008) · CNS Drugs · doi:10.2165/00023210-200822030-00003 · Cited by 185
Pilot Physical Activity Intervention Reduces Severity of ADHD Symptoms in Young Children
Smith, A. L., Hoza, B., Linnea, K. S., McQuade, J. D., Tomb, M. F., Vaughn, A. J., Shoulberg, E. K., & Hook, H. (2011) · Journal of Attention Disorders · doi:10.1177/1087054711417395 · Cited by 197
Medication Use Among Children <12 Years of Age in the United States: Results From the Slone Survey
Vernacchio, L., Kelly, J. P., Kaufman, D. W., & Mitchell, A. A. (2009) · PEDIATRICS · doi:10.1542/peds.2008-2869 · Cited by 168
Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder
Perrin, J. M., Friedman, R. A., Knilans, T. K., the Black Box Working Group, & Surgery, T. S. O. C. A. C. (2008) · Pediatrics · doi:10.1542/peds.2008-1573 · Cited by 161
Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents
Schelleman, H., Bilker, W. B., Strom, B. L., Kimmel, S. E., Newcomb, C., Guevara, J. P., Daniel, G. W., Cziraky, M. J., & Hennessy, S. (2011) · Pediatrics · doi:10.1542/peds.2010-3371 · Cited by 159
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation
Chen, Y., Jowett, S. M., Barton, P. M., Malottki, K., Hyde, C., Gibbs, J. S. R., Pepke-Zaba, J., Fry-Smith, A., Roberts, J., & Moore, D. (2009) · Health Technology Assessment · doi:10.3310/hta13490 · Cited by 148
Adverse Events Associated With Pediatric Spinal Manipulation: A Systematic Review
Vohra, S., Johnston, B. C., Cramer, K., & Humphreys, K. (2006) · PEDIATRICS · doi:10.1542/peds.2006-1392 · Cited by 147
Attention deficit hyperactivity disorder in adults
Rösler, M., Casas, M., Konofal, É., & Buitelaar, J. K. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.483249 · Cited by 151
Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review
Westover, A. N., & Halm, E. A. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-41 · Cited by 141
Attention Deficit/Hyperactivity Disorder: A Review and Update
Cormier, E. (2008) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2008.01.003 · Cited by 148
The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?
Kaye, S. S., & Darke, S. G. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03720.x · Cited by 139
Prescription stimulant medication misuse: Where are we and where do we go from here?
Weyandt, L. L., Oster, D. R., Marraccini, M. E., Guðmundsdóttir, B. G., Munro, B. A., Rathkey, E. S., & McCallum, A. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000093 · Cited by 138
Utilization of Pharmacologic Treatment in Youths with Attention Deficit/Hyperactivity Disorder in Medicaid Database
Winterstein, A. G., Gerhard, T., Shuster, J. J., ZITO, J. M., Johnson, M. R., Liu, H., & Saidi, A. S. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k143 · Cited by 131
Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder
Martínez-Raga, J., Knecht, C., Szerman, N., & Martínez, M. (2012) · CNS Drugs · doi:10.1007/s40263-012-0019-9 · Cited by 131
Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment: A Retrospective Cohort Study of Children, Adolescents and Young Adults Using the General Practice Research Database
McCarthy, S., Cranswick, N., Potts, L., Taylor, E., & Wong, I. C. K. (2009) · Drug Safety · doi:10.2165/11317630-000000000-00000 · Cited by 128
Predictors of mortality in patients with suspected propofol infusion syndrome
Fong, J. J., Sylvia, L. M., Ruthazer, R., Schumaker, G. L., Kcomt, M., & Devlin, J. W. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318180c1eb · Cited by 128
Parental Angst Making and Revisiting Decisions About Treatment of Attention-Deficit/Hyperactivity Disorder
Brinkman, W. B., Sherman, S. N., Zmitrovich, A. R., Visscher, M. O., Crosby, L., Phelan, K. J., & Donovan, E. (2009) · Pediatrics · doi:10.1542/peds.2008-2569 · Cited by 141
Methylphenidate and Risk of Serious Cardiovascular Events in Adults
Schelleman, H., Bilker, W. B., Kimmel, S. E., Daniel, G. W., Newcomb, C. W., Guevara, J. P., Cziraky, M. J., Strom, B. L., & Hennessy, S. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010125 · Cited by 124
Special Education Financing and ADHD Medications: A Bitter Pill to Swallow
Morrill, M. S. (2018) · Journal of Policy Analysis and Management · doi:10.1002/pam.22055 · Cited by 120
Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Winterstein, A. G., Gerhard, T., Shuster, J., Johnson, M., Zito, J. M., & Saidi, A. (2007) · Pediatrics · doi:10.1542/peds.2007-0675 · Cited by 119
Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder: An Update
Awudu, G. A. H., & Besag, F. (2014) · Drug Safety · doi:10.1007/s40264-014-0201-8 · Cited by 116
Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring
ZITO, J. M., Derivan, A., Kratochvil, C. J., Safer, D. J., Fegert, J. M., & Greenhill, L. L. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-24 · Cited by 114
Dietary Sensitivities and ADHD Symptoms: Thirty-five Years of Research
Stevens, L. J., Kuczek, T., Burgess, J. R., Hurt, E. A., & Arnold, L. E. (2010) · Clinical Pediatrics · doi:10.1177/0009922810384728 · Cited by 113
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults
Wilens, T. E., Morrison, N. R., & Prince, J. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.137 · Cited by 117
Do stimulant medications improve educational and behavioral outcomes for children with ADHD?
Currie, J., Stabile, M., & Jones, L. E. (2014) · Journal of Health Economics · doi:10.1016/j.jhealeco.2014.05.002 · Cited by 112
Understanding the Risk of Using Medications for Attention Deficit Hyperactivity Disorder with Respect to Physical Growth and Cardiovascular Function
Vitiello, B. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.11.010 · Cited by 113
Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the Treatment of Sarcoidosis-Associated Fatigue
Lower, E. E., Harman, S., & Baughman, R. P. (2008) · CHEST Journal · doi:10.1378/chest.07-2952 · Cited by 108
Use of ADHD drugs in the Nordic countries: a population-based comparison study
Zoëga, H., Furu, K., Halldórsson, M., Thomsen, P. H., Sourander, A., & Martikainen, J. E. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01607.x · Cited by 107
Blood Pressure and Heart Rate Over 10 Years in the Multimodal Treatment Study of Children With ADHD
Vitiello, B., Elliott, G. R., Swanson, J. M., Arnold, L. E., Hechtman, L. T., Abikoff, H., Molina, B. S. G., Wells, K., Wigal, T. L., Jensen, P. S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111705 · Cited by 106
Illicit use of prescription stimulants in a college student sample: A theory-guided analysis
Bavarian, N., Flay, B. R., Ketcham, P. L., & Smit, E. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.04.024 · Cited by 99
To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?
van de Loo-Neus, G. H. H., Rommelse, N., & Buitelaar, J. K. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.03.008 · Cited by 98
Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder
Weisler, R. H., Pandina, G., Daly, E., Cooper, K., & Gassmann-Mayer, C. (2012) · CNS Drugs · doi:10.2165/11631990-000000000-00000 · Cited by 97
Does Childhood Attention-Deficit/Hyperactivity Disorder Predict Risk-Taking and Medical Illnesses in Adulthood?
Ramos Olazagasti, M. A., Klein, R. G., Mannuzza, S., Belsky, E. R., Hutchison, J. A., Lashua-Shriftman, E. C., & Xavier Castellanos, F. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.11.012 · Cited by 94
Pediatric neuroenhancement
Graf, W. D., Nagel, S. K., Epstein, L. G., Miller, G., Nass, R. D., & Larriviere, D. (2013) · Neurology · doi:10.1212/wnl.0b013e318289703b · Cited by 94
Attention Deficit Hyperactivity Disorder Across the Lifespan: The Child, Adolescent, and Adult
Greydanus, D. E., Pratt, H. D., & Patel, D. R. (2007) · Disease-a-Month · doi:10.1016/j.disamonth.2007.01.001 · Cited by 98
Clinical trials bureaucracy: unintended consequences of well-intentioned policy
Califf, R. M. (2006) · Clinical Trials · doi:10.1177/1740774506073173 · Cited by 91
Complementary and Alternative Medical Therapies for Attention-Deficit/Hyperactivity Disorder and Autism
Weber, W. J., & Newmark, S. C. (2007) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.09.006 · Cited by 89
Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners
Brown, K. A., Samuel, S., & Patel, D. R. (2018) · Translational Pediatrics · doi:10.21037/tp.2017.08.02 · Cited by 87
Stimulants and Sudden Death: What Is a Physician to Do?
Wilens, T. E., Prince, J. B., Spencer, T. J., & Biederman, J. (2006) · PEDIATRICS · doi:10.1542/peds.2006-0942 · Cited by 86
Congenital heart disease: A primer for the pediatric neuropsychologist
Cassidy, A. R., Ilardi, D. L., Bowen, S. R., Hampton, L., Heinrich, K. P., Loman, M. M., Sanz, J. H., & Wolfe, K. R. (2017) · Child Neuropsychology · doi:10.1080/09297049.2017.1373758 · Cited by 88
Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants
Buitelaar, J. K., & Medori, R. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0056-1 · Cited by 80
Cardiovascular Risk of Stimulant Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder: Update and Clinical Recommendations
Hammerness, P. G., Perrin, J. M., Shelley-Abrahamson, R., & Wilens, T. E. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.07.018 · Cited by 80
Safety of therapeutic methylphenidate in adults: a systematic review of the evidence
Godfrey, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089809 · Cited by 77
Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis
Liu, H., Feng, W., & Zhang, D. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1217-x · Cited by 72
Attention Deficit Hyperactivity Disorder and the Athlete: An American Medical Society for Sports Medicine Position Statement
Putukian, M., Kreher, J. B., Coppel, D., Glazer, J. L., Mckeag, D., & White, R. D. (2011) · Clinical Journal of Sports Medicine · doi:10.1097/jsm.0b013e3182262eb1
Illicit drugs and cardiac arrhythmias in athletes
Furlanello, F., Serdoz, L. V., Cappato, R., & De Ambroggi, L. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3280ecfe3e · Cited by 70
Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study
Winterstein, A. G., Gerhard, T., Kubilis, P. S., Saidi, A. S., Linden, S., Crystal, S., Zito, J., Shuster, J. J., & Olfson, M. (2012) · BMJ · doi:10.1136/bmj.e4627 · Cited by 72
Psychostimulants in the Treatment of Depression
Orr, K., & Taylor, D. (2007) · CNS Drugs · doi:10.2165/00023210-200721030-00004 · Cited by 46
Chemical Cardiomyopathies: The Negative Effects of Medications and Nonprescribed Drugs on the Heart
Figueredo, V. M. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.031 · Cited by 68
Cardiovascular Effects of ADHD Therapies
Torres-Acosta, N., O’Keefe, J. H., O’Keefe, C. L., & Lavie, C. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.081 · Cited by 65
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies
Shier, A. C., Reichenbacher, T., Ghuman, H. S., & GHUMAN, J. K. (2012) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s6691 · Cited by 79
Involvement of Amphetamines in Sudden and Unexpected Death
Schumann, J., Gerostamoulos, D., Drummer, O. H., & Bollmann, M. D. (2009) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2008.00949.x · Cited by 64
Pilot Feasibility Study of Binaural Auditory Beats for Reducing Symptoms of Inattention in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Kennel, S., Taylor, A. G., Lyon, D., & Bourguignon, C. M. (2009) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2008.06.010 · Cited by 63
EEG biofeedback in the treatment of attention deficit hyperactivity disorder.
Friel, P. N. (2007) · PubMed · Cited by 58
Research in child and adolescent psychopharmacology: recent accomplishments and new challenges
Vitiello, B. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0414-3 · Cited by 58
Adverse drug interactions in dentistry
Hersh, E. V., & Moore, P. A. (2008) · Periodontology 2000 · doi:10.1111/j.1600-0757.2008.00224.x · Cited by 58
Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder
Hammerness, P., Wilens, T., Mick, E., Spencer, T., Doyle, R., McCreary, M., Becker, J., & Biederman, J. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.02.008 · Cited by 57
Impact of Acute Energy Drink Consumption on Blood Pressure Parameters: A Meta-analysis
Shah, S. A., Chu, B. W., Lacey, C. S., Riddock, I. C., Lee, M., & Dargush, A. E. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016656433 · Cited by 54
Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate
Treceño, C., Arias, L. H. M., Saínz, M., Salado, I., Ortega, P. G., Velasco, V., Jimeno, N., Escudero, A., Velasco, A., & Carvajal, A. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2348 · Cited by 47
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder
Huang, Y., & Tsai, M.-H. (2011) · CNS Drugs · doi:10.2165/11589380-000000000-00000 · Cited by 54
Grappling with the Medicated Self: The Case of ADHD College Students
Loe, M., & Cuttino, L. (2008) · Symbolic Interaction · doi:10.1525/si.2008.31.3.303 · Cited by 53
Possible adverse events in children treated by manual therapy: a review
Humphreys, B. K. (2010) · Chiropractic & Manual Therapies · doi:10.1186/1746-1340-18-12 · Cited by 51
Pharmacotherapy of ADHD in Adults
Wilens, T. E. (2008) · CNS Spectrums · doi:10.1017/s1092852900002960 · Cited by 50
Transition metal- and solvent-free double hydroboration of nitriles
Bedi, D., Brar, A., & Findlater, M. (2020) · Green Chemistry · doi:10.1039/c9gc04260a · Cited by 48
Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: A Brazilian sample study and literature review
Koneski, J. A. S., Casella, E. B., Agertt, F., & Ferreira, M. G. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.02.029 · Cited by 46
The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome
Green, T., Weinberger, R., Diamond, A. D., Berant, M., Hirschfeld, L., Frisch, A., Zarchi, O., Weizman, A., & Gothelf, D. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0042 · Cited by 46
Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder.
Gehricke, J., Hong, N., Whalen, C. K., Steinhoff, K. W., & Wigal, T. L. (2009) · Psychology of Addictive Behaviors · doi:10.1037/a0017441 · Cited by 46
Differential Effects of Predictors on Methylphenidate Initiation and Discontinuation Among Young People with Newly Diagnosed Attention-Deficit/Hyperactivity Disorder
Chen, C., Yeh, H.-H. H., Chen, K.-H., Chang, I., Wu, E. C., & Lin, K. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0107 · Cited by 43
Comorbidities in ADHD children treated with methylphenidate: a database study
Kraut, A. A., Langner, I., Lindemann, C., Banaschewski, T., Petermann, U., Petermann, F., Mikolajczyk, R., & Garbe, E. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-11 · Cited by 45
Treatment of ADHD With Stimulant Medications: Response to Nissen Perspective in The New England Journal of Medicine
Biederman, J., Spencer, T. J., Wilens, T. E., Prince, J. B., & Faraone, S. V. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000227883.88521.e6 · Cited by 42
Methylphenidate poisoning: An evidence-based consensus guideline for out-of-hospital management
Scharman, E. J., Erdman, A. R., Cobaugh, D. J., Olson, K. R., Woolf, A. D., Caravati, E. M., Chyka, P. A., Booze, L. L., Manoguerra, A. S., Nelson, L. S., et al. (2007) · Clinical Toxicology · doi:10.1080/15563650701665175 · Cited by 41
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults
Najib, J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.01.015 · Cited by 40
Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders
Auriel, E., Hausdorff, J. M., & Giladi, N. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318170576c · Cited by 40
Modeled Economic Evaluation of Alternative Strategies to Reduce Sudden Cardiac Death Among Children Treated for Attention Deficit/Hyperactivity Disorder
Denchev, P., Kaltman, J. R., Schoenbaum, M., & Vitiello, B. (2010) · Circulation · doi:10.1161/circulationaha.109.901256 · Cited by 38
Databases for pediatric medicine research in Europe—assessment and critical appraisal
Neubert, A. C., Sturkenboom, M., Murray, M. L., Verhamme, K. M. C., Nicolosi, A., Giaquinto, C., Ceci, A., & Wong, I. C. K. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1661 · Cited by 38
The diversion of stimulant medications among a convenience sample of college students with current prescriptions.
Gallucci, A. R., Martin, R. J., & Usdan, S. (2014) · Psychology of Addictive Behaviors · doi:10.1037/adb0000012 · Cited by 37
Drug-induced endocrine blood pressure elevation
Beck, K. R., Thompson, G. R., & Odermatt, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104311 · Cited by 38
Switching from Neurostimulant Therapy to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
Prasad, S., & Steer, C. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810010-00005 · Cited by 35
Long‐QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder
Zhang, C., Kutyifa, V., Moss, A. J., McNitt, S. A., Zaręba, W., & Kaufman, E. S. (2015) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12739 · Cited by 34
An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults
Kollins, S. H., Schoenfelder, E. N., English, J. S., Holdaway, A. S., Voorhees, E. E. V., O’Brien, B., Dew, R. E., & Chrisman, A. K. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.014 · Cited by 35
Medical, Nonmedical, and Illegal Stimulant Use by Sexual Identity and Gender
Philbin, M. M., Greene, E., Martins, S. S., LaBossier, N. J., & Mauro, P. M. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.05.025 · Cited by 34
Effects of Methylphenidate on Response to Oral Levodopa
Nutt, J. G., Carter, J. H., & Carlson, N. E. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.319 · Cited by 34
Parents’ Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD
Ahmed, R. A., Borst, J., Wei, Y. C., & Aslani, P. (2013) · Journal of Attention Disorders · doi:10.1177/1087054713499231 · Cited by 33
Four-Year Outcome in Psychopharmacologically Treated Adults With Attention-Deficit/Hyperactivity Disorder
Lensing, M. B., Zeiner, P., Sandvik, L., & Opjordsmoen, S. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07714 · Cited by 32
Basics and Dynamics of Neonatal and Pediatric Pharmacology
Seyberth, H. W., & Kauffman, R. E. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-20195-0_1 · Cited by 31
Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008
Kornfield, R., Watson, S., Higashi, A. S., Conti, R. M., Dusetzina, S. B., Garfield, C. F., Dorsey, E. R., Huskamp, H. A., & Alexander, G. C. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201200147 · Cited by 31
Pharmacologic Management of Excessive Daytime Sleepiness
Takenoshita, S., & Nishino, S. (2017) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2017.03.019 · Cited by 32

Authors: Nissen, S. E.
Affiliations: Cleveland Clinic (US)
Corresponding author: Nissen, Steven E.
ORCID: Nissen, Steven E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-04-06
Volume: 354
Issue: 14
Pages: 1445-1448
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp068049
OpenAlex: W2032285255
Cited by: 331
References: 6
Citations by year: 2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 10 · 2017: 8 · 2016: 11 · 2015: 14 · 2014: 19 · 2013: 25 · 2012: 28
FWCI: 26.17
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: attention deficit hyperactivity disorder, stimulants, cardiovascular risk, black box warning, drug safety, cardiovascular adverse events
MeSH terms: Adult, Central Nervous System Stimulants, Appetite Depressants, Attention Deficit Disorder with Hyperactivity, Cardiovascular Diseases, Child, Death, Sudden, Drug and Narcotic Control, Female, Humans, Male, Phenylpropanolamine, Sympathomimetics, United States, United States Food and Drug Administration, Ephedra

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ADHD Drugs and Cardiovascular Risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks